FDA approves new treatment for advanced ovarian cancer

On Dec. 19, the Food and Drug Administration (FDA) approved Rubraca (rucaparib) to treat women with advanced ovarian cancer who have been treated with two or more chemotherapies and whose tumors have the gene mutation deleterious BRCA as identified by an FDA-approved companion diagnostic test. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here